Dermatology
Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management.
19 Jan, 2022 | 08:15h | UTCRelated: Management of Dermatologic Adverse Events from Cancer Therapies
Treating Acne in Transgender Persons Receiving Testosterone: A Practical Guide.
18 Jan, 2022 | 09:23h | UTC
Phase 2 RCT: In patients with generalized pustular psoriasis, Spesolimab improved lesions at one week but was associated with infections and systemic drug reactions.
14 Jan, 2022 | 08:01h | UTCTrial of Spesolimab for Generalized Pustular Psoriasis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trial of Spesolimab for Generalized Pustular Psoriasis – Mount Sinai
RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.
14 Jan, 2022 | 07:57h | UTCEffect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary on Twitter
Study found proactive therapeutic drug monitoring (TDM) compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases https://t.co/yfJjyADaOT pic.twitter.com/JtOfQxFFDS
— JAMA (@JAMA_current) December 21, 2021
Review: Diagnosis and treatment of sexually transmitted infections.
13 Jan, 2022 | 08:38h | UTCDiagnosis and Treatment of Sexually Transmitted Infections: A Review – JAMA (free for a limited period)
RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).
12 Jan, 2022 | 08:43h | UTCRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to PFS than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. https://t.co/idtOgksg74 pic.twitter.com/vx1W9O4Dh6
— NEJM (@NEJM) January 5, 2022
Phase 3 trials of Tapinarof cream for plaque psoriasis.
16 Dec, 2021 | 08:49h | UTCPhase 3 Trials of Tapinarof Cream for Plaque Psoriasis – New England Journal of Medicine
Commentary: Topical tapinarof reduces severity of plaque psoriasis – HealthDay
Commentary on Twitter
In two trials of treatment for psoriasis with the topical aryl hydrocarbon receptor–modulating agent tapinarof, clearance of lesions occurred in a larger proportion of patients who used tapinarof cream than of those who used placebo. https://t.co/I4zgVFELhz pic.twitter.com/qT6lbaJK0U
— NEJM (@NEJM) December 10, 2021
Short Review: Lymphogranuloma venereum.
14 Dec, 2021 | 08:42h | UTCLymphogranuloma venereum – Canadian Medical Association Journal
RCT: Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone vs. Ipilimumab in patients with advanced melanoma.
5 Dec, 2021 | 23:07h | UTCEditorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology
Original Study: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma
Systematic Review: Phototherapy for atopic eczema.
3 Dec, 2021 | 10:03h | UTCPhototherapy for atopic eczema – Cochrane Library
Commentary on Twitter
New @CochraneSkin systematic review casts some light on the topic of visible #LightTherapy for treating atopic eczema – ( #eczema or #atopicdermatitis ) https://t.co/JsrQwdqMHr 32 studies, involving 1219 people included. pic.twitter.com/6SfmlA2kWZ
— Cochrane UK (@CochraneUK) November 6, 2021
Guideline on Cutaneous Angiosarcomas – Update 2021.
26 Nov, 2021 | 10:00h | UTCS1-Guideline Cutaneous Angiosarcomas – Update 2021 – Journal of the German Society of Dermatology
AAP Clinical Report: Biologics for Asthma and Allergic Skin Diseases in Children.
19 Nov, 2021 | 10:34h | UTCBiologics for Asthma and Allergic Skin Diseases in Children – Pediatrics
Systematic Review: Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors.
29 Oct, 2021 | 09:46h | UTCManagement of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review – JAMA Oncology (free for a limited period)
Podcast: Atopic Dermatitis Pearls.
27 Oct, 2021 | 01:01h | UTCAtopic Dermatitis Pearls – The Cribsiders
Guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery.
19 Oct, 2021 | 09:50h | UTC
Review: Management of infectious emergencies for the inpatient dermatologist.
17 Oct, 2021 | 21:06h | UTCManagement of Infectious Emergencies for the Inpatient Dermatologist – Current Dermatology Reports (if this link is paywalled, try this one)
RCT: Laser treatment not better than sham treatment on symptom severity in women with postmenopausal vaginal symptoms.
13 Oct, 2021 | 01:30h | UTCEffect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Time for a “Pause” on the Use of Vaginal Laser (free for a limited period)
Author Interview: Effect of Carbon Dioxide Laser vs Sham Therapy on Women With Postmenopausal Vaginal Symptoms
Commentary: Vagina lasering for postmenopausal women ‘may be placebo’ – The Guardian
Commentary on Twitter
In a randomized clinical trial among women with postmenopausal vaginal symptoms, treatment with fractional carbon dioxide laser vs sham treatment did not improve vaginal symptoms after 12 months https://t.co/XXv5edTLiL
— JAMA (@JAMA_current) October 12, 2021
Review: Life-threatening skin conditions presenting to critical care.
28 Sep, 2021 | 08:57h | UTCLife-threatening skin conditions presenting to critical care – BJA Education
A guide to the treatment of cellulitis and other soft-tissue infections.
16 Sep, 2021 | 09:47h | UTCA guide to the Tx of cellulitis and other soft-tissue infections – Journal of Family Practice
Viewpoint: Sentinel lymph node biopsy in cutaneous melanoma—where do we stand?
22 Aug, 2021 | 22:16h | UTCSentinel Lymph Node Biopsy in Cutaneous Melanoma—Where Do We Stand? – JAMA Dermatology (free for a limited period)
Guideline: Diagnosis and management of cutaneous lupus erythematosus – Classification, diagnosis, prevention, activity scores.
16 Aug, 2021 | 00:57h | UTC
German S3-Guideline on the treatment of Psoriasis vulgaris.
13 Aug, 2021 | 09:45h | UTC
Guideline: Diagnosis and management of cutaneous lupus erythematosus – Therapy, risk factors and other special topics.
12 Aug, 2021 | 08:55h | UTC
Brief review: Nails in systemic disease.
12 Aug, 2021 | 08:40h | UTCNails in systemic disease – Clinical Medicine Journal
Brief review: Immunobullous disease.
12 Aug, 2021 | 08:37h | UTCImmunobullous disease – Clinical Medicine Journal